AssetMark Inc’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.15M | Buy |
11,366
+518
| +5% | +$90.5K | ﹤0.01% | 874 |
|
|
2025
Q4 | $1.84M | Buy |
10,848
+5,499
| +103% | +$843K | ﹤0.01% | 872 |
|
|
2025
Q3 | $705K | Sell |
5,349
-77,769
| -94% | -$9.33M | ﹤0.01% | 1034 |
|
|
2025
Q2 | $8.82M | Buy |
83,118
+82,275
| +9,760% | +$8.94M | 0.02% | 448 |
|
|
2025
Q1 | $105K | Buy |
843
+116
| +16% | +$15.1K | ﹤0.01% | 1268 |
|
|
2024
Q4 | $89.5K | Buy |
727
+47
| +7% | +$5.54K | ﹤0.01% | 1276 |
|
|
2024
Q3 | $75.8K | Sell |
680
-36
| -5% | -$3.94K | ﹤0.01% | 1203 |
|
|
2024
Q2 | $76.4K | Buy |
716
+107
| +18% | +$11.8K | ﹤0.01% | 1153 |
|
|
2024
Q1 | $73.3K | Buy |
609
+169
| +38% | +$20.7K | ﹤0.01% | 1092 |
|
|
2023
Q4 | $54.1K | Buy |
440
+119
| +37% | +$14.8K | ﹤0.01% | 1143 |
|
|
2023
Q3 | $41.5K | Sell |
321
-13
| -4% | -$1.73K | ﹤0.01% | 1133 |
|
|
2023
Q2 | $41.4K | Buy |
334
+157
| +89% | +$21.1K | ﹤0.01% | 1126 |
|
|
2023
Q1 | $25.9K | Buy |
177
+3
| +2% | +$444 | ﹤0.01% | 1156 |
|
|
2022
Q4 | $27.7K | Sell |
174
-16
| -8% | -$2.35K | ﹤0.01% | 1154 |
|
|
2022
Q3 | $25K | Buy |
190
+13
| +7% | +$1.98K | ﹤0.01% | 1091 |
|
|
2022
Q2 | $28K | Sell |
177
-52
| -23% | -$8.01K | ﹤0.01% | 1053 |
|
|
2022
Q1 | $36K | Buy |
229
+66
| +40% | +$9.58K | ﹤0.01% | 981 |
|
|
2021
Q4 | $21K | Sell |
163
-82,976
| -100% | -$10.9M | ﹤0.01% | 1050 |
|
|
2021
Q3 | $10.8M | Buy |
83,139
+73,978
| +808% | +$11.2M | 0.05% | 215 |
|
|
2021
Q2 | $1.63M | Buy |
+9,161
| New | +$1.59M | 0.01% | 338 |
|
|
2020
Q2 | – | Sell |
-87
| Closed | -$9K | – | 1359 |
|
|
2020
Q1 | $9K | Buy |
87
+2
| +2% | +$259 | ﹤0.01% | 1006 |
|
|
2019
Q4 | $13K | Buy |
+85
| New | +$11.6K | ﹤0.01% | 993 |
|
|
2019
Q3 | – | Sell |
-24
| Closed | -$3K | – | 1366 |
|
|
2019
Q2 | $3K | Buy |
24
+21
| +700% | +$2.82K | ﹤0.01% | 1116 |
|
|
2019
Q1 | $0 | Sell |
3
-7
| -70% | -$913 | ﹤0.01% | 1440 |
|
|
2018
Q4 | $1K | Buy |
10
+7
| +233% | +$1.04K | ﹤0.01% | 1323 |
|
|
2018
Q3 | $1K | Hold |
3
| – | – | ﹤0.01% | 1346 |
|
|
2018
Q2 | $1K | Hold |
3
| – | – | ﹤0.01% | 1345 |
|
|
2018
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 1692 |
|
|
2017
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 1995 |
|
|
2017
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 1543 |
|
|
2017
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 1441 |
|
|
2017
Q1 | $0 | Sell |
3
-1
| -25% | -$130 | ﹤0.01% | 1360 |
|
|
2016
Q4 | $0 | Sell |
4
-225
| -98% | -$25.1K | ﹤0.01% | 1320 |
|
|
2016
Q3 | $28K | Sell |
229
-111
| -33% | -$15K | ﹤0.01% | 775 |
|
|
2016
Q2 | $48K | Buy |
340
+217
| +176% | +$32K | ﹤0.01% | 616 |
|
|
2016
Q1 | $16K | Sell |
123
-6,403
| -98% | -$797K | ﹤0.01% | 795 |
|
|
2015
Q4 | $917K | Sell |
6,526
-3,740
| -36% | -$518K | 0.02% | 290 |
|
|
2015
Q3 | $1.36M | Sell |
10,266
-3,039
| -23% | -$523K | 0.03% | 214 |
|
|
2015
Q2 | $2.34M | Sell |
13,305
-1,207
| -8% | -$217K | 0.05% | 165 |
|
|
2015
Q1 | $2.51M | Buy |
14,512
+4,582
| +46% | +$786K | 0.05% | 159 |
|
|
2014
Q4 | $1.63M | Sell |
9,930
-954
| -9% | -$158K | 0.04% | 232 |
|
|
2014
Q3 | $1.75M | Buy |
+10,884
| New | +$1.67M | 0.04% | 224 |
|
Other funds holding JAZZ
VPM
VCM
EC
AssetMark Inc's JAZZ Position: Q1 2026 in Review
AssetMark Inc increased its Jazz Pharmaceuticals (JAZZ) stake by 4.8% in Q1 2026, buying an estimated $90.5K and bringing the position to 11,366 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #874.
AssetMark Inc first reported a position in JAZZ in Q3 2014 and has held it in 42 quarters since. The position peaked at $10.8M in Q3 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- AssetMark Inc held 11,366 shares of Jazz Pharmaceuticals worth $2.15M as of Q1 2026.
- AssetMark Inc bought 518 Jazz Pharmaceuticals shares in Q1 2026, an estimated $90.5K.
- Jazz Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #874 holding.
- AssetMark Inc first reported a position in Jazz Pharmaceuticals in Q3 2014 and has held it in 42 quarters since.
- AssetMark Inc's Jazz Pharmaceuticals position peaked at $10.8M in Q3 2021.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.